x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243142
| Product Information | |
|---|---|
| CAS No. | 475479-34-6 |
| Synonyms | R1439; RO0728804 |
| Formula | C24H23NO5S |
| Molecular Weight | 437.51 |
| SMILES | CC1=C(CCOC2=CC=C(C[C@@H](C(O)=O)OC)C3=C2C=CS3)N=C(C4=CC=CC=C4)O1 |
| Target | PPAR |
| Product Description | Aleglitazar (R1439) is a potent dual PPARα/γ agonist, with IC50s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Color | White to yellow |
| Purity | 99.74% |
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years In solvent: -80°C, 2 years; -20°C, 1 year |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
